SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel's stock is trending following its latest earnings report, where strong Q4 results were overshadowed by weaker-than-expected Q1 guidance and acknowledged production bottlenecks. The community is sharply divided, with bears pointing to overvaluation and manufacturing challenges, while bulls emphasize Intel's strategic national security importance and long-term turnaround potential amid government backing.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is experiencing significant upward momentum, largely driven by rival Intel's recent disappointing earnings report and weak forward guidance, which the community interprets as a clear sign of AMD gaining market share. Traders are actively discussing the implications of Intel's struggles, with many anticipating new all-time highs for AMD amid strong underlying demand for high-performance chips and AI accelerators.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is seeing heightened interest driven by its Breakthrough Therapy Designation for pemvidutide, signaling strong potential in the competitive obesity and liver disease market. The community is actively discussing the drug's differentiated profile, including muscle-sparing weight loss, fueling speculation about an impending partnership or acquisition by a major pharmaceutical player. This robust sentiment is further amplified by its current valuation and notable short interest, pointing to a potential for significant price movements.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as news breaks of China approving H200 chip orders, fueling speculation about accelerating demand for its next-gen Rubin architecture and solidifying its role in global AI infrastructure. The community is actively debating its market performance, with many highlighting its expanding reach into diverse sectors like AI PCs and sovereign AI factories, especially in contrast to competitors' recent struggles.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics ($SNSE) is trending with intense community discussion centered on its extremely low share float and the potential for a massive short squeeze. While skepticism regarding the company's operational status and "pump and dump" claims is present, many anticipate a significant price surge, fueled by its strategic review and cash position as catalysts for a potential corporate event.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano Inc. is trending following news that its merger partner, Corvex, secured a long-term NVIDIA H200 GPU deployment to support AI workloads. The community is actively discussing the stock's low float and its connection to the booming AI sector, driving conversation around significant upside potential while some also express skepticism about the news as a potential pump and dump.

RYVYL Inc. is a financial technology company that develops software platforms and tools that are focused on providing global payment acceptance and disbursement capabilities. It offers an innovative payment platform-as-a-service that redefines global payment solutions, enabling seamless business-to-business, consumer-to-business, and peer-to-peer transactions worldwide. The company leverages advanced electronic payment technology to deliver seamless financial solutions across global markets. It operates through two geographical segments: North America and International. The company was founded on April 10, 2007 and is headquartered in San Diego, CA.

Ryvyl Inc

Ryvyl Inc. is experiencing significant trading activity driven by its extremely low public float and high volume, sparking community discussions around a potential short squeeze. Recent filings for its merger with Roundtable, including a significant strategic partnership with The Hockey News, are fueling speculation about its future as a Web3 digital media and fintech platform. The company's ongoing efforts to maintain NASDAQ compliance are also a key focus among investors.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending as the community debates the implications of its TikTok deal, with many anticipating a significant price surge and short squeeze on news of its finalization. While some see the recent dip as a prime buying opportunity, betting on its AI infrastructure and cloud potential, others remain cautious, citing debt concerns and potential "sell the news" volatility.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is seeing significant attention after finalizing a strategic AI licensing partnership in Africa, including a pilot program with Nelson Mandela University. Traders are actively discussing the stock's potential for a short squeeze, citing its thin float, high short interest, and elevated borrow fees as factors amplifying current momentum within the AI microcap sector.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is actively discussed as its Q2 earnings report on February 3rd approaches, notably without a preceding business update. This has fueled community speculation that the company is poised to meet or exceed revenue and EPS expectations, driving strong calls for a short squeeze given its perceived undervaluation in the crucial AI infrastructure sector. Despite ongoing discussions around gross margins, many view SMCI as a pivotal player poised for significant movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top & Flop ETF Areas of 2025 (Revised)

Silver, gold & platinum ETFs (SLVP, SILJ, GOEX) crushed it in 2025, while MEME & VIXY lagged.

Santa Rally Falls Short: Top ETF Performers of December

Santa Rally fizzled as markets stumbled, but ETFs tied to cannabis (MSOS, WEED), metals (SLV, PPLT) and space (UFO) surged.

Top & Flop ETF Areas of 2025

Silver, gold & platinum ETFs (SLVP, SILJ, GOEX) crushed it in 2025, while MSOS, MEME & VIXY lagged amid policy, hype & calm markets.

<ul class="summary-bullets"><li>Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.&nbsp;</li><li>The executive order directs Trump’s administration to initiate the steps needed for the classification shift.</li></ul><p>Shares of Tilray Brands, Aurora Cannabis and Trulieve Cannabis pulled back on Thursday after an early rally sparked by U.S. President Donald Trump’s executive order to ease federal restrictions on marijuana lost momentum, as investors pared gains following the initial reaction to the policy move.</p><p>Shares of TLRY and ACB fell 5% and 3% respectively at the time of writing while TCNNF dropped 17%.&nbsp;</p><h2 class="st-heading-2">Trump Pushes Medical Marijuana</h2><p>President Donald Trump on Thursday signed an executive order to reschedule marijuana to make it less restrictive and available for “legitimate medical uses.”</p><p>Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research. Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.</p><p>“We have people begging for me to do this, people that are in great pain for decades,” Trump said while referring to patients suffering from extreme pain and incurable diseases including cancer. The executive order directs Trump’s administration to initiate the steps needed for the classification shift.</p><p>“Schedule III status will allow research studies to incorporate real-world evidence and models that can assess the health outcomes of medical marijuana and legal CBD products while focusing on long-term health effects in vulnerable populations like adolescents and young adults,” the White House said in a statement.</p><p>State regulations on cannabis are currently complex. While a few U.S. states currently permit the recreational use of cannabis, some allow it for medical purposes.</p><h2 class="st-heading-2">How Did Trump Decide?</h2><p>According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-18/trump-signs-order-to-reclassify-marijuana-in-industry-win">report</a> from Bloomberg, Trump came to the decision following discussions with Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services Administrator Mehmet Oz as well as cannabis-industry leaders including Trulieve Cannabis Corp CEO Kim Rivers. As per the report, the Centers for Medicare &amp; Medicaid Services is also expected to complete a plan to test making some Medicare patients eligible for therapies derived from cannabinoids.</p><p>Jazz Pharmaceuticals’ Epidiolex is currently the only drug approved by the U.S. Food and Drug Administration composed of CBD, a psychoactive compound found in cannabis.</p><h2 class="st-heading-2">Tilray Plans Expansion With Trump’s Push</h2><p>Tilray, a producer and distributor of medical and adult-use cannabis, subsequently confirmed plans to advance its U.S. medical cannabis operations with the formation of a unit called Tilray Medical USA, Inc. The unit aims to introduce medical-grade cannabis products in targeted therapeutic formats, the company said.</p><p>“This action [executive order] aligns regulation with a vast body of scientific and medical data supporting cannabis medical use and safety, economic progress, and a healthcare-focused framework, while creating a more credible foundation for medical cannabis research, clinical development, and regulatory clarity,” Tilray CEO Irwin D. Simon said.</p><h2 class="st-heading-2">Other Cannabis Firms Respond To Policy Change</h2><p>Cresco Labs applauded the executive order terming it a “cultural turning point” and a “historic shift.” Trulieve too applauded the decision while <a href="https://stocktwits.com/symbol/SMG">Scotts Miracle-Gro</a> expressed support highlighting that 39 states already legalize cannabis in some form. Scotts expects to combine its Hawthorne Gardening company subsidiary, which provides nutrients, lighting and other supplies to legal cannabis growing operations, with a cannabis company in 2026.</p><p><a href="https://stocktwits.com/symbol/HITI">High Tide</a> said that it is exploring structures that would allow it to expand its Canna Cabana retail brand into the U.S. through licensing.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TLRY">TLRY</a> and <a href="https://stocktwits.com/symbol/CGC">CGC</a> trended in the ‘extremely bullish’ territory at the time of writing. Sentiment around <a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF</a> (MSOS), which tracks American operators, followed suit.</p><p>TLRY and CGC shares are down 8% and 39% this year, respectively.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-eyes-ex-tesla-employee-sterling-anderson-as-potential-successor-to-ceo-mary-barra-report/cLegDrmRErL">General Motors Eyes Ex-Tesla Employee Sterling Anderson As Potential Successor To CEO Mary Barra: Report</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

Tilray, Aurora Cannabis, Trulieve Pull Back After Trump Marijuana Order Rally Runs Out Of Steam

Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research.

Equity

Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide, but is instead aimed at improving medical marijuana and cannabidiol research.


Cannabis ETFs Soar Double-Digits on Friday: Here's Why

Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

<ul class="summary-bullets"><li>Bloomberg reported that the Centers for Medicare &amp; Medicaid Services (CMS), which runs the Medicare program, is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</li><li>MSOS and YOLO, two key cannabis sector-focused funds, gained 3.4% and 2.7%, respectively.</li><li>The Trump administration seems to be backing cannabis as an industry, following its previous comments regarding CBD and reclassifying marijuana.</li></ul><p>Cannabis&nbsp;stocks advanced on Wednesday following a report speculating that certain U.S Medicare patients could soon be eligible to receive coverage for CBD under a new initiative.</p><p>CBD, or cannabidiol, is a compound found in cannabis and used to treat sleep disorders, anxiety, pain, and inflammation. Some research suggests it may also treat cancer symptoms. The drug is sold as gummies, pet treats, and skincare supplements.</p><h2 class="st-heading-2"><strong>Cannabis Stocks Rally</strong></h2><p>Tilray Brands’ shares rose 4.8%, while the over-the-counter stocks of Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries gained between 2% to 5.6%. Shares of Innovative Industrial Properties, a real estate investment trust (REIT) that buys and leases specialized cannabis cultivation facilities, rose 1.1%.</p><p>On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/TLRY">TLRY</a> shifted to ‘extremely bullish’ from ‘bullish,’ while that for&nbsp;<a href="https://stocktwits.com/symbol/CURLF">CURLF</a> shifted to ‘bullish’ from ‘neutral.’ The sentiment was ‘bullish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">GTBIF</a>, and ‘bearish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">TCNNF</a> and&nbsp;<a href="https://stocktwits.com/symbol/IIPR">IIPR</a> as of the last reading.&nbsp;</p><p>The&nbsp;<a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF (MSOS)</a>, which tracks U.S. cannabis companies exclusively, and the&nbsp;<a href="https://stocktwits.com/symbol/YOLO">AdvisorShares Pure Cannabis ETF (YOLO)</a>, which also tracks overseas companies and cannabis-adjacent businesses, rose 3.4% and 2.7%, respectively.</p><h2 class="st-heading-2"><strong>CMS Initaitive</strong></h2><p>The rally came after Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors">reported</a> that the Centers for Medicare &amp; Medicaid Services (CMS) is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</p><p>Details of the proposed program aren’t available, but an early version of the plan focused on seniors in oncology and palliative care settings, according to a summary viewed by the news agency.</p><p>Unnamed sources told Bloomberg that Howard Kessler, a payments financier who has advocated for expanded CBD access, met with Health and Human Services Secretary Robert F. Kennedy Jr. about the issue last month</p><h2 class="st-heading-2"><strong>A Trump Boost?</strong></h2><p>The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-cannabis-stocks-lose-high-premarket-after-surge-triggered-by-trumps-post/chDDTJ9R3BB">said</a> in a video post in September.</p><p>The previous month, Trump said his administration was weighing a move to reclassify marijuana as a less dangerous drug under federal law.</p><p>That said, doubts over cannabis efficacy in healthcare remain. A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267">recent study</a> funded by the Food and Drug Administration suggested that prolonged use of CBD may cause liver toxicity, while other research suggests it can interfere with other medications, harm male reproductive health, and pose potential risks to children and pregnant women.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/holiday-shopping-could-soar-to-a-record-1-trillion-this-year-with-online-spending-blasting-to-new-highs/cL5eLqVREW6">Holiday Shopping Could Soar To A Record $1 Trillion This Year, With Online Spending Blasting To New Highs</a></p>

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

<ul class="summary-bullets"><li>The provision bans online, gas station, and corner store sales of intoxicating hemp products, including delta-8, starting in 2026.</li><li>The rules are set to take effect in 2026, creating new compliance requirements for producers and retailers.</li><li>Tilray criticized the legislation, warning that it may prompt consumers to turn to unregulated alternatives.</li></ul><p>Cannabis stocks were trading lower in afternoon trade on Thursday amid broader weakness in the equities market after the U.S. government funding bill to end the shutdown included language tightening rules on hemp-derived THC products.</p><p>Tilray Brands (TLRY) and Canopy Growth (CGC) shares fell more than 7%, while Green Thumb Industries (GTBIF) dipped 2.4%. Retail sentiment was ‘bearish’ around&nbsp;<a href="https://stocktwits.com/symbol/TLRY">Tilray’s stock</a>, according to Stocktwits data.&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">Green Thumb Industries’ stock</a> saw retail sentiment trending in ‘bullish’ territory over the past day, while retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/CGC">Canopy Growth’s stock</a> trended in the ‘extremely bullish’ zone.</p><h2 class="st-heading-2">New Hemp Rules Take Effect in 2026</h2><p>The funding legislation includes a provision banning the “unregulated sale of intoxicating hemp-based or hemp-derived products, including delta-8, from being sold online, in gas stations, and corner stores,” according to a Senate Appropriations Committee summary. The rules are set to take effect in 2026, creating new compliance requirements for producers and retailers.</p><p>Tilray criticized the move, calling it a “misguided” step that could push consumers toward unregulated alternatives. “Prohibition and overly restrictive measures do not work,” the company said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tilray.com/news-releases/news-release-details/tilray-brands-condemns-misguided-prohibitionist-measures-and">statement</a> on Wednesday.</p><h2 class="st-heading-2">Retail Traders See Upside</h2><p>One Stocktwits user noted that the federal hemp ban increases the upside and that it’s a good opportunity to buy the dip.</p><p><stembedurl>https://stocktwits.com/techvested/message/636064141</stembedurl></p><p>Another user highlighted the optimism of investors buying cheap shares, anticipating that a rescheduling announcement for cannabis may be on the horizon later this year or next year.&nbsp;</p><p><stembedurl>https://stocktwits.com/Thumbszilla/message/636090102</stembedurl></p><p>The regulatory changes also weighed on broader cannabis-focused exchange-traded funds. AdvisorShares Pure U.S. Cannabis ETF (<a href="https://stocktwits.com/symbol/MSOS">MSOS</a>) fell more than 5% in afternoon trade on Thursday, while the Cambria Cannabis ETF (<a href="https://stocktwits.com/symbol/TOKE">TOKE</a>) dropped 1.4%.&nbsp;</p><p><strong>Read also:&nbsp;</strong><a href="https://stocktwits.com/news-articles/markets/equity/circle-stock-gains-after-jpmorgan-turns-bullish-cathie-woods-ark-invest-buys-the-dip/cLP9RYgRE3X"><strong>Circle Stock Gains Pre-Market After JPMorgan Turns Bullish, Cathie Wood’s Ark Invest Buys The Dip</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Cannabis Stocks Drop As Shutdown Deal Tightens Hemp-THC Rules

The U.S. government funding bill to end the shutdown included language tightening rules on hemp-derived THC products.

Trade War or Not, Specific Industry ETFs Are in Sweet Spots

Trade war jitters rise, but ETFs like MSOS, SILJ, SGDJ, BBC, WISE & CTEX shine on solid fundamentals, offering either safe havens or growth potential.

From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects 

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism. 

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

Policy uncertainty from Trump

Earnings & guidance

Options / dealer positioning

Liquidity & algos

Markets are reacting to a mix of policy headlines, earnings, and positioning. We want to hear what you think is driving volatility the most right now.

MSOS
AdvisorShares Pure US Cannabis ETF

Feed

News

Sentiment

Fundamentals

Info

Latest MSOS News

MSOSAdvisorShares Pure US Cannabis ETF